Download Electronic Trading 17th May 2004

Update on barcodes &
medicines-associated issues
in NHS
February 23rd 2012
Franklin Room, IBM United Kingdom Limited, 76/78 Upper Ground,
Judie Finesilver MRPharmS
e-Business Pharmacist
Commercial Medicines Unit,
Department of Health
[email protected]
07785 573 914
What’s the current
message ?
•NHS dm+d
•GS1
•EU Falsified Medicines Directive
•Projects from CMU
NHS Dictionary of Medicines
and Devices – dm+d
•Website
•Name, strength, form of a medicine
•No ambiguity
•Enter the GTIN
http://www.dmd.nhs.uk/
No supply
chain
informaton..
No GTIN
GTIN Global Trader Item
Number
GTIN- used to be known as EAN
Managed by GS1- Global Standards 1
Population of GTIN field currently ~ 20%
Working with BSA to appear in the browser
Link between clinical and supply
chain will support patient safety
Example
Similar looking product- very
different clinical action
Wrong label attached to
product
What else could the
barcode carry?
Newer and cleverer carriers.
QR code : 2D data matrix code
Quick Response
Code
EU Falsified Medicines
Directive
http://www.manufacturingchemist.com/news/article_page/EC_cons
ults_on_Falsified_Medicines_Directive/71100
Safety Features?
Tamper-Evident Seal
Unique Identifier
Process
All POMs to be included
and Medicines to be risk assessed for
exclusion where the product is a POM or for
inclusion where the product is a prescription medicine.
Risk assessments proposed to be based on cost, volume, risk
to health.
Issues
•Cross industry issues: secondary care /
homecare – who has responsibility for tracking
and recording of codes?
•Issues in primary care: connectivity and
networking issues raised – verification response
time needs to be short
Discussion needed!
What are the most appropriate step(s) in the process
for identification to happen ? –
•Point of dispensing only
•Point of dispensing plus random points along the
supply chain
•Point of dispensing plus systematically along the
supply chain
Who is going to pay for this?
What happens if legislation changes?
Does this need enforcing – won’t happen otherwise?
Pan European issues:
•Europe are seeking harmonisation across Europe on
standards, scanning mechanism (GS1 Or similar?) and repository
approach
•When importing, products will need to be checked
out of one countries repository and into another
•Who will hold the verification repository? options
include: Centralised Europe repository, National Repository or a
stakeholder owned repository (joint pharmacy and industry
associations via not for profit organization). Complications include
some countries may want to collaborate on setting up joint
repositories and some may wish autonomy).
•
Benefits
•Patient safety –the most important
•Efficiency improvements (though wholesalers voiced
concerns over additional workload if scanning each pack was
imposed)
•Aid investigation of errors
•Aid product recall process
•Having a unique identifier will ensure counterfeiters can’t
produce large batches of product – less cost effective
•Companies that adopt 2D will be seen as having a
differentiating factor when UK making purchasing
decisions
Risk
manufacturers not willing to adopt will
leave the UK market –
what impact will that have on UK supply
chain?
Summary!
Current Projects for CMU
KPI reports• JAC v4.47 and Crystal X1
•Ascrbe v8
Stockholding Report• 2 email addresses
Homecare
Homecare
Want to identify the homecare spend
•Request to hospital pharmacy to include the
word (Home) in the supplier names
•And possibly to include the word (Home) in the
product Description.
•Onerous
•Difficult
•Are you affected?
To Summarise
•NHS dm+d- add product into Data base
•GS1- not for profit global organisation- manage coding
carriers
•EU Falsified Medicines Directivetamper evidence and unique identification of product.
Risk assessment for opt-out for all POMs
for opt-in for all Ps
•Projects for CMU-
KPIs; Stockholding;
Homecare
Update on barcodes &
medicines-associated issues
in NHS
February 23rd 2012
Franklin Room, IBM United Kingdom Limited, 76/78 Upper Ground,
Judie Finesilver MRPharmS
e-Business Pharmacist
Commercial Medicines Unit,
Department of Health
[email protected]
07785 573 914